An FDA advisory committee just voted 15-2 that the benefits of the experimental anticlotting drug rivaroxaban outweigh the risks, Dow Jones Newswires reports. That's good news for Johnson & Johnson, which would sell the drug in [...]
Thursday, March 19, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment